Business
-
According to the Centenary Institute, the New South Wales COVID-19 Vaccine Acceleration Research Grants Program has awarded a grant worth AU$995,867 to researchers at the Centenary Institute and the University of Sydney to support development… Read more . . .
-
Vistagen, which is developing two pherine-based nasal sprays licensed from Pherin Pharmaceuticals (PH10 and PH94B), announced that it has reached an agreement to acquire Pherin and its entire pipeline. According to Vistagen, the deal includes… Read more . . .
-
Inhaled nitric oxide (iNO) delivery device developer Third Pole Therapeutics announced that it has received a $32 million equity investment “from a large medical device innovator.” In February 2022, the company announced the closing of… Read more . . .
-
According to Aridis Pharmaceuticals, the Cystic Fibrosis Foundation has made a $4.85 million investment in Aridis common stock to support continued development of AR-501 nebulized gallium citrate for the treatment of chronic lung infections in CF… Read more . . .
-
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a new patent covering Evoke’s Gimoti metoclopramide nasal spray. The new patent (No. 11,517,545), which expires in 2038, is titled “Treatment… Read more . . .
-
Pulmocide announced that it has closed a $52 million a Series C extension round, with the proceeds to be used for continued development of its PC945 inhaled opelconazole for the treatment of invasive pulmonary Aspergillosis (IPA).… Read more . . .
-
After receiving a “Study May Proceed” letter from the FDA, Vistagen has announced plans for a Phase 1 trial of a re-formulated version of PH10 pherin nasal spray. The new Phase 1 study is expected… Read more . . .
-
Nuance Pharma has announced a deal with DKSH Business Unit Healthcare for commercialization of Bentrio, an API-free, bentonite-based OTC nasal spray for protection against allergens and viruses, in Hong Kong and Macau. Bentrio is currently marketed… Read more . . .
-
Belgium-based Hyloris Pharmaceuticals announced that it has added an intranasal TRPV1 agonist (HY-083) for the treatment of idiopathic rhinitis to its pipeline. TRPV1 (transient receptor potential cation channel subfamily V member 1) is overexpressed in… Read more . . .
-
CDMO Kindeva Drug Delivery, which specializes in inhalation, intradermal, and transdermal drug delivery, has announced that it will merge with fellow Altaris Capital Partners company Meridian Medical Technologies, which specializes in autoinjectors. Altaris acquired Kindeva… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal